Rahul Singhvi, Sc.D.
National Resilience, Inc.
CEO and Director
Rahul Singhvi, Sc.D., M.B.A., is Co-Founder, CEO, and Director of National Resilience, Inc (Resilience), a biopharmaceutical manufacturing and technology company launched in November 2020 with initial capital of more than $800 million. He has more than 25 years of experience in leadership roles in the Bio/Pharmaceutical industry.
Prior to taking the helm at Resilience, Dr. Sanghvi was an Operating Partner at Flagship Pioneering, a Boston-based life-sciences innovation firm, where he was responsible for founding and operating companies launched from Flagship’s innovation foundry, Flagship Labs. Before joining Flagship, Dr. Singhvi was the Chief Operating Officer of Takeda’s Vaccine Business Unit, where he was responsible for worldwide vaccine CMC and manufacturing operations. During his six-year tenure (2013 to 2019) at Takeda, the vaccine business grew to over 500 employees and created an industry leading late-stage pipeline of vaccine candidates against dengue, norovirus, and the Zika virus. Before Takeda, Dr. Singhvi was President and CEO of Novavax, Inc. (2005 to 2011), where he transformed the company from a specialty pharmaceutical business to a vaccine-development company with vaccine candidates against influenza and respiratory syncytial virus. Dr. Singhvi’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing.
Dr. Singhvi serves on the Executive Advisory Board of the Leonard Davis Institute of Health Economics at the University of Pennsylvania and on the Scientific Advisory Board of the anti-microbial resistance research group at the Singapore–MIT Advance Research and Technology program. He is a mentor instructor in the Undergraduate Projects Opportunity Program at the Massachusetts Institute of Technology (MIT) and is a visiting lecturer at the University College London.
Dr. Singhvi graduated as the top ranked chemical engineer from the Indian Institute of Technology, Kanpur, India and obtained both his M.S. and Sc.D. chemical engineering degrees from MIT. He received a M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.